Irit Ben-Chelouche

Director of Business Development, Harvard Medical School

Displaying: 1 - 10 of 38 Results

Novel Biochemical and Computational Approaches to Increase Mass Spectrometry Sensitivity

Mass spectrometry (MS) has become the leading protein identification technique. Current mass spectrometry methods rely on tandem MS/MS detection, where a prepared peptide digestion sample is injected into the mass spectrometer and analyzed by its…

Investigators

  • Marc W. Kirschner
  • Mingjie Dai

New Raman Microscopy Technique Accelerates Digital Pathology

Current methods for pathological diagnosis of diseases require laborious and costly sample processing steps and provide inherently qualitative information. Moreover, batch to batch variations in staining intensity results in highly variable images,…

Investigators

  • Marc W. Kirschner
  • Seungeun Oh

One-Seq: A highly scalable diagnostic for SARS-CoV-2 and its variants

The COVID-19 pandemic has highlighted the need for highly scalable and sensitive viral diagnostics, together with identification of viral variants. One-Seq is a novel diagnostic method with three key advantages: it is highly scalable, allowing a…

Investigators

  • Marc W. Kirschner
  • Mingjie Dai
  • George M. Church

Isolating live cells after high-throughput, long-term, time-lapse microscopy

Researchers led by Johan Paulsson have engineered a high-throughput microfluidic device for multigenerational culturing, imaging, and tracking of single-cell lineages. The platform is highly customizable and is compatible with many cell types,…

Investigators

  • Johan Paulsson

Machine learning to accelerate diagnostics and therapeutics for COVID-19

The COVID-19 pandemic demands a rapid response of science, diagnostics, and therapeutics. Debora Marks’ lab at Harvard Medical School aims to accelerate those efforts using predictive models of the SARS-CoV2-19 sequences and 3D structures. The lab’s…

Investigators

  • Debora Marks

Novel adjuvants to enhance adaptive immune response of vaccines

Researchers in the lab of Ulrich von Andrian have discovered a novel adjuvanting behavior of a clinically approved and well-tolerated class of medicines known as bisphosphonates. The team is hoping to collaborate with manufacturers of COVID-19…

Investigators

  • Ulrich H. von Andrian

Exo-site Enzyme Inhibitor Discovery Platform for Oncology Therapeutics

A startup emerging from David Liu's lab intends to commercialize a small-molecule enzyme inhibitor discovery platform to generate more potent drugs with higher specificity. (Image credit: Rose Lincoln/Harvard Staff Photographer.)Off-target drug…

Investigators

  • David R. Liu

Continuous directed evolution of aminoacyl-tRNA synthetases to alter amino acid specificity and enhance activity

DESCRIPTION Functions of various biotherapeutics can often be enhanced by modifying individual amino acid residues. However, the current approaches rely on existing natural amino acid chemistry. Approaches that provide new chemical “handles” will…

Investigators

  • David R. Liu

Evolution of Sequence-Defined Highly Functionalized Nucleic Acid Polymers

DESCRIPTION Template-directed synthesis of modified DNA sequences can provide a rich source of material for generating new therapies featuring modified nucleic acid polymers. The Liu lab has previously developed pioneering methods to generate…

Investigators

  • David R. Liu

Modulating the Blood-Brain Barrier (BBB) to enable delivery of drugs and development of therapeutics

The blood–brain barrier (BBB) helps maintain a constant, optimal environment for neuronal function through a combination of barriers and selective transport systems that regulate the passage of wanted and unwanted molecules. While important for…

Investigators

  • Chenghua Gu

Page 1 of 4